1 / 4

Outcome of Lu177 PSMA Therapy in India | Cost of Lutetium or Lu177 PSMA Therapy

Lutetium-177 PSMA therapy is a new, cutting-edge treatment for prostate cancer that is showing great promise. This therapy uses a radioactive isotope called lutetium-177, which targets and kills cancer cells while sparing healthy tissue. Lutetium-177 PSMA therapy is currently being used in clinical trials and has been shown to be effective in treating prostate cancer. This treatment is non-invasive just like Actinium (Ac225) PSMA Therapy and has very few side effects, making it an attractive option for patients with this disease.<br><br>

fontansurgery
Download Presentation

Outcome of Lu177 PSMA Therapy in India | Cost of Lutetium or Lu177 PSMA Therapy

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. OutcomeofLu177 PSMATherapy inIndia Introduction Lutetium-177 PSMA therapyisanew,cutting-edgetreatmentforprostatecancerthat isshowinggreatpromise.Thistherapyusesaradioactiveisotopecalled lutetium-177, whichtargetsandkillscancercellswhilesparinghealthytissue.Lutetium-177 PSMA therapyiscurrentlybeingusedin clinicaltrialsandhasbeenshown to beeffectivein treatingprostatecancer. Thistreatmentisnon-invasive justlikeActinium(Ac225) PSMA Therapy and has very few side effects, making it an attractive option for patientswith thisdisease. LatestTherapyforbesttreatmentofProstateCancerinIndia Lu177Therapyisa true breakthroughinprostate cancertreatment. Ithasproved effectiveinnotonlyreducingthesizeoftumoursbutalsoinstoppingthecancerous cellsfrommultiplying.Thistherapyhassuccessfullybeenableto achievelong-term remission, thus helping patientslead a betterqualityoflifeposttreatment. Thistherapyhasproveditselfto beausefultherapyformanagementofmetastatic prostate cancerforwhich othertypesoftreatmentshave failed. WhoiseligibleforLutetium-177Therapy? There are very few hospitals in India that offer such an progressive cancer treatment option like this. Patients suffering from advanced and metastatic prostate cancer are eligible forthistherapythatactuallycombinestherapywith diagnostics. Before yourLu177 therapygetsstarted, adiagnosticscancalled Ga-68PSMAPET CTwillbeperformed toensure thatthetherapy’sradiation accuratelytargetstheright areas duringtreatment. Lutetium-177 therapy is exclusively used for males suffering from prostate cancer that has originated in the prostate area and for whom other lines of treatment have failed to offerrelief. Howdoes Lutetium-177Therapy work? PSMAisakindofprotein foundonthemembraneofprostate cells,andisbelievedto have severalcellularfunctions. The cancerous prostate tumorscreate extremelyhigh levelsoflutetiumascompared to epitheliumcellsofthe prostate. Itisalmost1000 timeshigherthan anormalcellofthe prostate.

  2. Youalso need to note thatifprostate cancerhasspread tootherbodyorgansthenthis PSMAcan be foundin those areas aswell. • DuringtheLu177PSMAtherapy,lutetiumwhichisaradiation-basedtreatment,uses a molecule forattaching itselfto thePSMAreceptorspositioned on the cancercells. TheLu177 releasesbeta radiationthatefficientlydamagescancercellsand, overa periodoftime, itdestroysthem. • WhendothebestdoctorsforprostatecancerinIndia recommendLu177 PSMA Therapy? • Lutetium-177 PSMATherapy isa quite precisetherapyused formanagementof metastatic ProstateCancerorwhenyourProstate Cancerwouldnolongerbe responsive to otherkindsoftreatment. • The therapy is recommended to patients diagnosed to have Advanced Castration- resistant Metastatic Prostate Cancer with indication of tumour increasing in size. Cancerprogressionmaybe seen in the formof: • Pain aggravation orotherdeterioratingsymptoms due to thedisease • RiseinSerumPSA levels • Increasein thesizeorquantityofthe metastatic lesionson Ga68PSMAscans orCT/MRI • Yourdoctorwill notsuggestyouLu177PSMATherapyincaseof-Yourdoctorwill notsuggestyouLu177PSMATherapyincaseof– • Extremehaematologicalcompromise • Poor functionof thekidneys • Treatment Durationfor Lu177 PSMATherapy • AsfarastreatmentscheduleofLu177 Therapyisconcerned,patientsmajorlyundergo 3to4treatmentcyclesatagapof8to12weeks.Thenumberoftherapycyclesand the intervalbetween2cyclesvariesfromoneindividualtoanother. Italsodepends upon individual’sresponse to previouscycles. • Theaverage dosage ofLu PSMATherapy givenvariesintherangeof5.5–11GBq foreachtreatmentcycleandthedosesareprimarilybasedonpretreatmentdose assessment. Ionizingradiationdose thatgetsabsorbedbyahumanbodyisprecisely measured,calculatedandassessed byatreatingdoctorwhileplanningthetherapy.

  3. Onthedayoftreatment,yourdoctorwill admityouasaninpatientinthehospitalina SpecialisedHighDoseRadioisotope TherapyUnitforthepurposeofmonitoringand also radiation protection. OutcomeofLu177PSMATherapy inIndia The outcomeofLu177 PSMAtherapydependsuponseveralfactorslike– nature of tumourofyourprostatecancer, the preliminaryGleasonScore, the extenttowhich disease has spread and also theresponsestopriortherapiesyouhave undergone. Ingeneral,morethan 70%-80%ofpatients areknownto haveshowna reduction in PSAlevelsandalsoshrinkageoftumourspostLu177 PSMAtherapyinIndia.Not onlythis,youwillbeglad toknowthatalmostall patientsshowareductioninpain and improvementinoverallhealth assoonastheyreceive the 2nddoseofthis therapy. Lutetium-177(Lu-177)PSMA (Prostate-SpecificMembraneAntigen)therapyisthe newestdevelopmentin thetreatmentofprostatecancer. Thistherapyishighlyprecise, asLu-177elementsgetfixed directlyto thePSMAreceptorthatispresentatthe surfaceofprostatecancercells,thuscausingdamagetotheirDNAdirectlyby emittinga minoramountofBeta-radiation. Damage tonearbytissuesandrelatedsideeffectsarereducedbytargetingthecancer cells directly withradiation.Accordingto a clinicalstudy,peoplewhoweregiven PSMA therapy along with standard prostate cancer treatment lived longer as compared tothosewhoreceived onlystandardtreatment.The studyalsoshowed improvementindiseaseprogressionamongstpeoplewhoreceivedLu-177 PSMA therapy. CostofLutetiumor Lu177 PSMATherapyin India The bestprostate cancerhospital in Indiaisnotonlyoneoftheworld’smost advancedcentersforNuclearMedicinebutalsooffersthelowestcostformost advancedtreatmentslikeLu177Therapy. Itisthemostcosteffective centreinIndia offeringthistherapyathalfofthecostthatyoumayenduppaying incountrieslike MalaysiaorThailand,and1/3rdofthecostyouwouldpayifyoutraveltoGermany oranyotherdeveloped nationofferingthistreatment.Contactustodaytoknowthe costoflutetium-177 PSMATherapy. TAG-OutcomeofLu177 PSMATherapyinIndia,CostofLutetiumorLu177 PSMA Therapyin India

More Related